MOTS-c Administration Routes in Research: What Studies Used

Short answer: the routes in the literature are laboratory methods, not human protocols

MOTS-c is a short mitochondrial-derived peptide encoded within the mitochondrial 12S rRNA region. Review articles describe it as a regulator of metabolic stress responses that has attracted interest for therapeutic exploration, while also noting that the field remains largely preclinical (PMID 36761202). A second review framed the peptide primarily around its role in preventing metabolic disorders in experimental models (PMID 36677050). Because of that, every "administration route" discussed below comes from a study design — a way researchers delivered a test article to cells or animals — and not from any established clinical regimen.

This page is for educational purposes only and is not medical advice; consult a licensed physician before making decisions about any health condition or substance. Nothing here describes a protocol, and no route described below should be read as a suggestion to replicate it.

Why route matters for a peptide of this size

MOTS-c is a small peptide of roughly sixteen amino acids. General peptide pharmacology explains why delivery method is a central design decision in this literature:

• Proteolysis. Peptides are substrates for digestive and plasma proteases, so the gastrointestinal tract is a hostile environment for an intact peptide.
• Permeability. Hydrophilic peptides cross intestinal epithelium poorly compared with small molecules.
• Short half-life. Small unmodified peptides are cleared rapidly, which pushes preclinical designs toward repeated parenteral administration.
• Tissue access. Studies asking about muscle, islet, liver, joint or tumour biology need the peptide to reach that tissue at a measurable concentration.

These constraints are the practical reason most published MOTS-c work has used either direct exposure in cell culture or parenteral administration in rodents rather than feeding the peptide.

Route 1: direct exposure in cell culture (in vitro)

The simplest "route" in the literature is not a route at all — the peptide is added to culture medium at a defined concentration, bypassing absorption and clearance entirely. A 2022 report in Peptides used this approach and reported that MOTS-c promoted muscle differentiation in vitro (PMID 35842023). A 2024 mechanistic study likewise combined cellular and biochemical work, and researchers reported that MOTS-c directly bound and activated casein kinase 2 (CK2) in the context of skeletal muscle function (PMID 39559755).

Researchers choose cell-culture exposure when the question is mechanistic: which protein does the peptide engage, which pathway shifts, what happens in a specific cell type. The trade-off is that in vitro concentrations say nothing about whether the same exposure is achievable in a living organism by any route.

Route 2: intraperitoneal injection in rodents

Intraperitoneal (IP) injection — delivery into the abdominal cavity — is the workhorse route of rodent metabolic research. It is fast, requires no specialised equipment, tolerates larger volumes than subcutaneous injection, and produces rapid systemic exposure through peritoneal and portal absorption. It is also a route with no human clinical equivalent for this peptide.

The foundational 2015 Cell Metabolism paper that characterised MOTS-c gave the peptide to mice in vivo and reported that treatment promoted metabolic homeostasis and reduced diet-induced obesity and insulin resistance, with effects linked to the folate–methionine cycle and AMPK activation (PMID 25738459). Later disease-model work followed the same general template of systemic peptide administration to animals. In a gestational diabetes model, researchers reported that MOTS-c relieved hyperglycaemia and insulin resistance (PMID 34798268). A 2025 study in Experimental & Molecular Medicine reported that the peptide prevented pancreatic islet cell senescence and delayed diabetes onset in its model system (PMID 40855115).

Similar systemic designs appear outside metabolism. A 2024 study in Gut reported an antiviral role for MOTS-c during hepatitis B virus infection through mitochondrial remodelling (PMID 37788894), and a 2024 Advanced Science paper reported suppression of ovarian cancer progression via effects on USP7-mediated LARS1 deubiquitination (PMID 39321430). In musculoskeletal models, researchers reported that MOTS-c attenuated immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration (PMID 38170165), and a 2025 study reported attenuation of mitochondrial dysfunction, pyroptosis and cartilage degradation in osteoarthritis through an Nrf2-dependent mechanism (PMID 41043625).

Route 3: subcutaneous and intramuscular injection

Subcutaneous and intramuscular delivery are the routes most commonly used for peptide therapeutics in human medicine, because they avoid first-pass metabolism and give reasonably predictable absorption. In the MOTS-c literature these routes appear far less often than intraperitoneal dosing, largely because the dominant animal models were established in metabolic laboratories where IP injection is standard.

Where researchers have studied muscle biology, the relevant consideration is not simply the injection site but whether the peptide reaches muscle tissue at an active concentration. The CK2-binding study framed MOTS-c as acting directly within skeletal muscle signalling (PMID 39559755), and the atrophy study reported tissue-level changes in lipid infiltration during immobilization (PMID 38170165). Neither of those findings establishes a comparative advantage for one parenteral route over another in humans; that comparison has not been reported in the papers reviewed here.

Route 4: oral administration — what the literature does and does not cover

"Can MOTS-c be given orally?" is one of the most searched questions about this peptide, and the honest answer from the verified literature is that oral delivery of the peptide itself is not the approach these studies used. The published work summarised on this page delivered MOTS-c to cells directly or to animals parenterally. Reviews of the peptide discuss its therapeutic potential while treating delivery and translation as open problems rather than solved ones (PMID 36761202, PMID 36677050).

One 2024 study illustrates an alternative strategy that is sometimes confused with oral peptide dosing. Researchers reported that pyrroloquinoline quinone — a small dietary compound, not the peptide — alleviated mitochondrial damage in a radiation-induced lung injury model in a MOTS-c-dependent manner (PMID 39259217). That design targets the MOTS-c axis with an orally tractable molecule rather than delivering the peptide through the gut. It is a meaningful distinction: evidence that a pathway can be engaged by a dietary compound is not evidence that a peptide survives digestion.

Route 5: intranasal and other mucosal routes

Intranasal delivery is used in peptide research when investigators want to bypass hepatic first-pass metabolism or target the central nervous system. It appears in the broader mitochondrial-derived peptide and neuropeptide fields, but the verified MOTS-c papers summarised here did not report intranasal administration as their method. Readers encountering claims about nasal MOTS-c should note that those claims are not supported by the studies cited on this page.

Route comparison as used in research

Bioavailability findings by route: what was and was not measured

A frequent misconception is that preclinical peptide papers report bioavailability percentages by route. In this evidence set they generally do not. The abstracts summarised above reported biological and mechanistic outcomes — changes in insulin sensitivity, muscle differentiation, islet senescence, viral replication, tumour progression, cartilage integrity — rather than plasma concentration–time curves or route-to-route bioavailability comparisons (PMID 25738459, PMID 40855115, PMID 41043625). Reviews of the peptide accordingly discuss translation as an open question (PMID 36761202).

That absence matters for interpretation. Without published pharmacokinetics by route, statements comparing oral, nasal and injected MOTS-c exposure in humans are not grounded in the studies cited here.

"On an empty stomach" and fasting: what the research actually studied

Another common search concerns whether fasting state matters. In the preclinical designs described above, animals received the peptide by injection, so gastric contents were not part of the delivery pathway, and the studies were not constructed to compare fed versus fasted administration. What the literature does address is the peptide's relationship to metabolic stress and nutrient handling: the original characterisation reported effects on the folate–methionine cycle, AMPK signalling and insulin sensitivity in mice (PMID 25738459), and review coverage places MOTS-c within metabolic-disorder biology more broadly (PMID 36677050). Those are statements about physiology, not about meal timing around administration.

Tolerability and Adverse Events: What Studies Report

The verified papers summarised here were designed as efficacy and mechanism studies in cells and animal models, and their abstracts emphasised biological outcomes rather than structured safety endpoints (PMID 34798268, PMID 38170165). Review articles discussing therapeutic exploitation likewise treat clinical safety characterisation as work still to be done (PMID 36761202). No human adverse-event profile by administration route is described in this evidence set, and absence of reported harm in short animal experiments is not the same as demonstrated safety.

Limitations of the route evidence

1. Species. Findings come from rodents and cultured cells; route behaviour differs across species.
2. Route mismatch. Intraperitoneal injection, the most common in vivo method here, has no routine human analogue.
3. Missing pharmacokinetics. The abstracts reviewed did not report comparative bioavailability by route.
4. Formulation variation. Peptide purity, vehicle and stability differ between laboratories and affect outcomes.
5. Regulatory status. MOTS-c is a research compound; it is not an approved medicine, and material sold for laboratory use is labelled research-use-only.

Taken together, the literature describes a peptide studied almost entirely through direct cellular exposure and parenteral administration in animals. Researchers reported consistent interest in its metabolic and mitochondrial biology, while the questions of how — or whether — it can be delivered effectively in humans by any route remain unanswered in these publications.

References

• MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation (Frontiers in Endocrinology, 2023)
• The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance (Cell Metabolism, 2015)
• The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus (Pharmacological Research, 2022)
• MOTS-c modulates skeletal muscle function by directly binding and activating CK2 (iScience, 2024)
• Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination (Advanced Science, 2024)
• Novel function of MOTS-c in mitochondrial remodelling contributes to its antiviral role during HBV infection (Gut, 2024)
• MOTS-c Functionally Prevents Metabolic Disorders (Metabolites, 2023)
• Mitochondrial-derived microprotein MOTS-c attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration (American Journal of Physiology. Endocrinology and Metabolism, 2024)
• Pyrroloquinoline Quinone Alleviates Mitochondria Damage in Radiation-Induced Lung Injury in a MOTS-c-Dependent Manner (Journal of Agricultural and Food Chemistry, 2024)
• Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes (Experimental & Molecular Medicine, 2025)
• MOTS-c promotes muscle differentiation in vitro (Peptides, 2022)
• MOTS-c attenuates mitochondrial dysfunction induces pyroptosis and cartilage degradation in osteoarthritis via an Nrf2-Dependent Mechanism (Free Radical Biology & Medicine, 2025)